What STEP 3 measured, and what it was never powered to detect
What was pre-specified, what was exploratory, and what was calculated afterwards by people who did not run the trial.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Protein and training
Where the familiar figures come from, what populations they were measured in, and how far the extrapolation reaches.
Ask where the number came from and the answer is usually a review article citing a review article. The Journal has traced the chain for the figures quoted most often in consumer material, and the terminus is generally one of three trials in resistance-trained young adults under moderate energy restriction. Those are good studies. They enrolled nobody over sixty, nobody with a body mass index above thirty-five, and nobody losing weight at the rate this drug class produces.
The figures in circulation — commonly one and a half to two grams of protein per kilogram of body weight daily, sometimes expressed as a floor of around a hundred grams — are traceable. The most-cited primary source is a randomised trial in resistance-trained young men under a substantial energy deficit, comparing a higher against a lower protein intake with supervised training and controlled feeding; the higher-intake group gained lean mass and lost more fat over four weeks.1 Supporting evidence comes from a large meta-analysis of protein supplementation during resistance training, which found a benefit to lean mass accrual that plateaued at around one and a half to one point six grams per kilogram daily.2
Both are good studies. Neither enrolled anybody over about thirty-five, anybody with obesity, or anybody losing weight at more than a small fraction of the rate this drug class produces. The plateau figure in particular is a plateau for training-induced accrual in weight-stable or mildly deficit conditions, and its application as a preservation target during a twenty per cent weight reduction is an extrapolation rather than a finding.
The Journal quotes these numbers because they are the best available and states their provenance because the provenance is the argument.
A ratio requires a denominator and this one has at least three in common use. Per kilogram of current body weight, one and a half grams gives a hundred and eighty grams a day for a person weighing a hundred and twenty kilograms — an intake that is difficult on a normal appetite and close to unachievable on a suppressed one. Per kilogram of a reference or ideal body weight, the same ratio gives perhaps a hundred and five grams. Per kilogram of measured lean mass, higher ratios are conventional and the absolute target lands somewhere between the two.
Guidance in the obesity literature generally uses reference weight or an adjusted weight for precisely this reason, and consumer material generally uses current weight without saying so, which inflates the target by a third or more in the population most likely to be reading it. A person then fails to meet an inflated target and concludes they are losing muscle.
The Journal reports protein targets against an explicitly named denominator, every time, and regards a gram-per-kilogram figure without a stated denominator as uninformative. Where a source does not say which weight it means, that is worth noticing rather than resolving by assumption.
The trials measured mass. Nobody measured whether the participants got weaker, and that measurement costs almost nothing.
On the missing endpointTwo syntheses are worth separating. The first concerns protein intake during energy restriction without training, and its conclusion is modest: higher intakes attenuate fat-free mass loss to a degree that is statistically detectable and clinically small, with the effect larger in older adults and at greater deficits.3 The second concerns protein plus resistance training, where the effect is larger and more consistent, and where the protein and the training are difficult to separate because they interact.
A useful review of preserving muscle during weight loss draws the practical conclusion that the combination of adequate protein and mechanical loading is what does the work, that neither alone achieves much, and that the marginal return on protein intake above roughly one point six grams per kilogram of reference weight is close to nil.4 That last point is the one most often dropped: the dose-response curve flattens, and intakes of three grams per kilogram — which appear in consumer advice with some regularity — have no supporting evidence and a real opportunity cost in an appetite that only accommodates so much food.
None of these syntheses included a participant taking an incretin. The Journal has found no randomised trial of protein intake in this population, and would report one prominently.
| Endpoint | Measured in a randomised trial? | Where |
|---|---|---|
| Areal BMD, hip and spine | Yes, as a secondary analysis | S-LiTE bone analysis |
| Bone turnover markers | Yes, small studies | Investigator-initiated |
| Bone geometry or microarchitecture | No | — |
| Incident fracture | No | — |
| Falls | No | — |
| Absence from this table means the Journal could not find a pre-specified randomised measurement, not that no observational data exists. Observational fracture data in weight loss is confounded in both directions. | ||
A Danish randomised trial remains the only controlled test of the obvious question. After an eight-week low-energy diet producing approximately thirteen kilograms of weight loss, participants were randomised for one year to supervised exercise alone, liraglutide 3.0 mg alone, both combined, or placebo.5 The combination arm achieved the largest weight reduction and, more relevantly here, the most favourable composition outcome: body fat percentage fell roughly twice as much in the combination group as in either single-intervention group, and the exercise arms preserved lean mass better than the drug-alone arm.
Three qualifications belong with that result. The exercise was supervised and substantial — two group sessions and two individual sessions weekly, with a vigorous-intensity target — which is not what most people mean by adding exercise. The agent was liraglutide at 3.0 mg daily, producing considerably less weight loss than the current agents, so whether the interaction scales to a twenty per cent reduction is unknown. And the trial began after weight had already been lost, so it is a maintenance study rather than an induction study.
With those stated, it is the best evidence in the field and it points in the direction the general advice already points.
Four things accompany every composition number in these pages. The instrument, because DXA, magnetic resonance, bioimpedance and creatine dilution are not interchangeable and the choice frequently determines the sign of the result. The sample size of the substudy rather than of the parent trial, because the parent trial size is irrelevant to the composition finding and quoting it is misleading. The definition used — total lean mass, lean soft tissue, appendicular lean mass or fat-free mass — because these differ by several kilograms in the same person. And whether the figure is a proportion of body mass or an absolute quantity.
Where a source omits any of the four, we say so rather than guessing, and where we have had to convert between definitions we show the conversion. This is more cumbersome than the alternative and it is the only way we have found to write about this subject without producing sentences that are technically true and practically misleading.
Readers who find a figure in these pages that lacks its instrument and its sample size have found an error, and the standards desk would like to hear about it at standards@compoundjournal.com.
A category confusion arrives in the Journal postbag with some regularity, and it is worth addressing directly. The four independent testing services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — analyse the contents of a vial. They report chromatographic purity, identity by mass, sometimes peptide content, and in the case of the verification services, what they were able to establish about a supplier. None of them measures anything about a person.
A certificate stating 98.7 per cent purity for a batch supplied by WWB, SSA or KP is silent on that customer’s body composition, and a low-purity result does not explain a disappointing DXA scan. The two questions are answered by different instruments in different buildings, and conflating them produces a particular kind of dead end in which somebody spends several hundred pounds on analytical testing to investigate a clinical question.
The reverse confusion also occurs: a satisfactory laboratory panel or a favourable body-composition scan is offered as evidence that a vial contained what its label claimed. It is not evidence of that either. Compounds sold for research use only are not approved for human use, and nothing in this section should be read as advice about using them.
Two things follow practically and only two. Eating adequate protein and loading the skeleton during rapid weight loss are supported by general physiology, carry negligible risk, and are worth doing. Expecting either to prevent lean-mass loss outright is not supported by anything, and treating a fall in a DXA number as a failure of adherence is a misreading of what the number can tell you.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
I have read your protein tables twice and I still cannot work out what I should eat. I appreciate that this is the honest position but it is not a useful one for a person in a supermarket.
— K. Erdmann, Leipzig
It is a fair complaint about a real limitation. What we can say is that the defensible range is narrower than the disagreement suggests, that the denominator matters more than the ratio, and that a clinician or dietitian can convert a range into a number for your body in a way that a magazine cannot.
Three vendors have now sent me marketing material claiming their product preserves lean mass during GLP-1 treatment, two of them citing your publication as a source for the underlying composition figures. You may want to know that.
— Z. Karadzic, Novi Sad
We did not, and we are grateful. Quoting our reporting of a substudy alongside an unevidenced product claim is a misuse of it, and the standards desk has written to all three.
I am sixty-eight, I have lost nineteen kilograms over fourteen months, and my consultant has twice told me my lean mass is fine on the basis of a handheld bioimpedance device in the clinic corridor. Having read your piece on what that device measures, I am no longer sure what I have been reassured about.
— J. Halloway, Dundee
Nor are we. A handheld device measures impedance across the upper body and infers the rest, and the inference is least reliable exactly where you sit: older, substantial weight change, changing hydration. That is not a criticism of your consultant’s judgement, which may be sound on other grounds, but the device is not the evidence for it.
What was pre-specified, what was exploratory, and what was calculated afterwards by people who did not run the trial.
A great deal of practice has grown up around intermittent schedules. The randomised evidence for any of them is, as far as the Journal can establish, nil.
The recommendation survives scrutiny. The reasoning offered for it frequently does not.
The evidence base is one secondary analysis, several small studies and a large amount of extrapolation from bariatric surgery.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A design note rather than a result: what the comparator was, and what that permits you to conclude.